Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer

Pancreatic cancer consists of a heterogenous bulk of tumor cells and stroma cells which contribute to tumor progression by releasing angiogenic factors. Those factors can be detected as circulating serum factors. We performed a compartment-specific analysis of tumor-derived and stroma-derived angiogenic factors to identify biomarkers and molecular targets for the treatment of pancreatic cancer. Kryo-frozen tissue from primary ductal adenocarcinomas (n = 51) was laser-microdissected to isolate tumor and stroma tissue. Expression of 17 angiogenic factors (angiopoietin-2, follistatin, GCSF, HGF, interleukin-8, leptin, PDGF-BB, PECAM-1, VEGF, matrix metalloproteinase -1, -2, -3, -7, -9, -10, -12, and -13) was analyzed using a multiplex elisa assay for tissue-derived proteins and corresponding serum. Our study reveals a compartment-specific expression profile for several angiogenic factors and matrix metalloproteinases. ROC analysis of corresponding serum samples reveals MMP-7 and MMP-12 as strong classifiers for the diagnosis of patients with pancreatic cancer vs. healthy control donors. High expression of tumor-derived PDGF-BB and MMP-1 correlates with prolonged survival in univariate and multivariate analysis. In conclusion, a distinct expression patterns for angiogenic cytokines and MMPs in pancreatic cancer and surrounding stroma may implicate them as novel targets for cancer treatment. Tumor-derived PDGF-BB and MMP-1 are significant and independent prognostic markers for poor survival.

[1]  Umar Mahmood,et al.  Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. , 2015, Cancer cell.

[2]  C. Pilarsky,et al.  Genomics of pancreatic ductal adenocarcinoma. , 2014, Hepatobiliary & pancreatic diseases international : HBPD INT.

[3]  S. Pothula,et al.  The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer. , 2014, Carcinogenesis.

[4]  Stephen A. Sastra,et al.  Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.

[5]  P. Kornprat,et al.  Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients , 2013, British Journal of Cancer.

[6]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[7]  P. Kornprat,et al.  Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer , 2013, British Journal of Cancer.

[8]  S. Bojesen,et al.  MicroRNA biomarkers in whole blood for detection of pancreatic cancer. , 2013, JAMA.

[9]  M. Büchler,et al.  Advanced-stage pancreatic cancer: therapy options , 2013, Nature Reviews Clinical Oncology.

[10]  Yibin Kang,et al.  The metastasis-promoting roles of tumor-associated immune cells , 2013, Journal of Molecular Medicine.

[11]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[12]  S. Choi,et al.  Serum CA19–9, cathepsin D, and matrix metalloproteinase‐7 as a diagnostic panel for pancreatic ductal adenocarcinoma , 2012, Proteomics.

[13]  D. Jäger,et al.  Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Derek S. Chan,et al.  The Pancreas Cancer Microenvironment , 2012, Clinical Cancer Research.

[15]  Alexander A. Fingerle,et al.  The role of stroma in pancreatic cancer: diagnostic and therapeutic implications , 2012, Nature Reviews Gastroenterology &Hepatology.

[16]  W. Greenhalf,et al.  New biomarkers and targets in pancreatic cancer and their application to treatment , 2012, Nature Reviews Gastroenterology &Hepatology.

[17]  G. Sauter,et al.  ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients , 2012, International journal of cancer.

[18]  A. Marx,et al.  ALCAM (CD166) Expression and Serum Levels in Pancreatic Cancer , 2012, PloS one.

[19]  R. Holder,et al.  Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test , 2012, British Journal of Cancer.

[20]  Carlos Cuevas,et al.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[21]  M. Kudo,et al.  Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer. , 2012, Japanese journal of clinical oncology.

[22]  Zainab N. Khan,et al.  Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. , 2012, Cancer cell.

[23]  R. Lothe,et al.  ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis , 2012, Gut.

[24]  R. Kalluri,et al.  Blockade of PDGF receptor signaling reduces myofibroblast number and attenuates renal fibrosis. , 2011, Kidney international.

[25]  R. Kalluri,et al.  The role of stromal myofibroblast and extracellular matrix in tumor angiogenesis. , 2011, Genes & cancer.

[26]  Gerald C. Chu,et al.  Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma , 2011, Proceedings of the National Academy of Sciences.

[27]  M. Koch,et al.  Overexpression of ZEB2 at the Invasion Front of Colorectal Cancer Is an Independent Prognostic Marker and Regulates Tumor Invasion In Vitro , 2011, Clinical Cancer Research.

[28]  M. Koch,et al.  Invasion front‐specific expression and prognostic significance of microRNA in colorectal liver metastases , 2011, Cancer science.

[29]  M. Koch,et al.  Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer , 2011, BMC Cancer.

[30]  D. Edwards,et al.  Matrix metalloproteinases: protective roles in cancer , 2011, Journal of cellular and molecular medicine.

[31]  M. Koch,et al.  Correlation of Circulating Angiogenic Factors with Circulating Tumor Cells and Disease Recurrence in Patients Undergoing Curative Resection for Colorectal Liver Metastases , 2011, Annals of Surgical Oncology.

[32]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[33]  D. Owen,et al.  Absence of MMP2 Expression Correlates with Poor Clinical Outcomes in Rectal Cancer, and Is Distinct from MMP1-Related Outcomes in Colon Cancer , 2011, Clinical Cancer Research.

[34]  M. Koch,et al.  Natural Killer Cells are Scarce in Colorectal Carcinoma Tissue Despite High Levels of Chemokines and Cytokines , 2011, Clinical Cancer Research.

[35]  Malte Buchholz,et al.  Stromal biology and therapy in pancreatic cancer , 2010, Gut.

[36]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[37]  M. Osman,et al.  Decreased Blood Flow with Increased Metabolic Activity: A Novel Sign of Pancreatic Tumor Aggressiveness , 2009, Clinical Cancer Research.

[38]  W. Scheithauer,et al.  Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  R. Kalluri,et al.  Tumor stroma derived biomarkers in cancer , 2009, Cancer and Metastasis Reviews.

[40]  S. Bhatia,et al.  The Impact of Lymph Node Number on Survival in Patients With Lymph Node-Negative Pancreatic Cancer , 2008, Pancreas.

[41]  Kunihiro Tsuchida,et al.  Follistatin Suppresses the Production of Experimental Multiple-Organ Metastasis by Small Cell Lung Cancer Cells in Natural Killer Cell–Depleted SCID Mice , 2008, Clinical Cancer Research.

[42]  H. Kocher,et al.  Analysis of mortality rates for pancreatic cancer across the world. , 2008, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[43]  L. Ellis,et al.  Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. , 2007, The Journal of clinical investigation.

[44]  T. Ohtsuka,et al.  The Hypoxic Environment in Tumor-Stromal Cells Accelerates Pancreatic Cancer Progression via the Activation of Paracrine Hepatocyte Growth Factor/c-Met Signaling , 2007, Annals of Surgical Oncology.

[45]  M. Mcmahon,et al.  Redefining the R1 resection in pancreatic cancer , 2006, The British journal of surgery.

[46]  Thomas Lengauer,et al.  ROCR: visualizing classifier performance in R , 2005, Bioinform..

[47]  Christian Pilarsky,et al.  Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes , 2005, Oncogene.

[48]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[49]  L. B. Chen,et al.  Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer , 2000, Journal of surgical oncology.

[50]  J. Forster,et al.  Significance of lymph node metastases in patients with pancreatic cancer undergoing curative resection. , 1996, American journal of surgery.

[51]  S. Yagi,et al.  Hepatobiliary & pancreatic diseases international : HBPD INT. , 2015 .

[52]  C. Iacobuzio-Donahue,et al.  Cancer gene profiling in pancreatic cancer. , 2010, Methods in molecular biology.

[53]  L. Way,et al.  Prognostic indicators for survival after resection of pancreatic adenocarcinoma. , 1993, American journal of surgery.

[54]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.